Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06843551 · ClinicalTrials.gov registry record · Phase 2
The Miami "EMPIRE" Trial - Eradication of Metastatic Pancreatic Cancer With Immuno-Radiation
A Phase 2 study of Metastatic Pancreatic Cancer and Metastatic Pancreatic Ductal Adenocarcinoma, sponsored by Benjamin Spieler.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT06843551: Recruiting Phase 2 study of Metastatic Pancreatic Cancer and Metastatic Pancreatic Ductal Adenocarcinoma, sponsored by Benjamin Spieler.
NCT06843551 is a Phase 2 study of Metastatic Pancreatic Cancer and Metastatic Pancreatic Ductal Adenocarcinoma that is actively recruiting participants, run by Benjamin Spieler. The registered enrollment target is 20 participants, below the 106-participant average among 32 other Metastatic Pancreatic Cancer trials with a reported enrollment target (81% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06843551, a Phase 2 study of Metastatic Pancreatic Cancer and Metastatic Pancreatic Ductal Adenocarcinoma, is actively recruiting participants, sponsored by Benjamin Spieler.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to assess if radiation therapy (which uses high-energy radiation to damage or destroy cancer cells) combined with immune checkpoint inhibitors (medications that helps the body recognize and attack cancer cells) will be beneficial for patients with metastatic pancreatic ductal adenocarcinoma.
Primary Outcome
The Clinical Benefit Rate (CBR) among participants will be reported. CBR is the number of participants achieving complete response (CR), partial response (PR) or stable disease after start of study therapy. Response will be assessed using Immune-related Response Evaluation Criteria in Solid Tumors (iRECIST) 1.1 criteria.
Conditions Studied
Interventions
- RADIATION Stereotactic Body Radiation Therapy
- DRUG Balstilimab
- DRUG Botensilimab
Study Locations (1)
Florida
- University of Miami - Miami
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2025-06-18 |
| Est. Completion | 2030-08-01 |
| Phase | Phase 2 |
What NCT06843551 shows while recruiting
NCT06843551 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 106-participant average among 32 other Metastatic Pancreatic Cancer trials with a reported enrollment target (81% lower).
The record links to 2 conditions, with Metastatic Pancreatic Cancer appearing as the primary indexed condition, and to 3 interventions - of which Stereotactic Body Radiation Therapy is the first listed.
NCT06843551 reports a single indexed study location in Florida.
Frequently Asked Questions
What is clinical trial NCT06843551 about?
NCT06843551 is a clinical study titled "The Miami "EMPIRE" Trial - Eradication of Metastatic Pancreatic Cancer With Immuno-Radiation". The purpose of this study is to assess if radiation therapy (which uses high-energy radiation to damage or destroy cancer cells) combined with immune checkpoint inhibitors (medications that helps the body recognize and attack cancer cells) will be beneficial for patients with metastatic pancreatic d...
What is the current status of trial NCT06843551?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2025-06-18. Estimated completion is 2030-08-01.
What conditions does trial NCT06843551 study?
This clinical trial studies the following conditions: Metastatic Pancreatic Cancer, Metastatic Pancreatic Ductal Adenocarcinoma.
What interventions are being tested in trial NCT06843551?
The interventions under investigation include: Stereotactic Body Radiation Therapy (RADIATION), Balstilimab (DRUG), Botensilimab (DRUG).
Who is sponsoring clinical trial NCT06843551?
This trial is sponsored by Benjamin Spieler, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06843551 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Pancreatic Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06843551's enrollment target sits among peer trials
20 30th of 32 higher than 3 of 32 other Metastatic Pancreatic Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Metastatic Pancreatic Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer
RECRUITING · Phase 2
-
Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors
RECRUITING · Phase 2
-
Multi-agent Low Dose Chemotherapy GAX-CI Followed by Olaparib and Pembro in Metastatic Pancreatic Ductal Cancer.
RECRUITING · Phase 2
-
Proglumide and Chemotherapy for Metastatic Pancreatic Cancer
ACTIVE NOT RECRUITING · Phase 2
-
A Study of Glipizide to Treat High Blood Sugar in People With Pancreatic Cancer
ACTIVE NOT RECRUITING · Phase 2
-
Nivolumab + Ipilimumab + Radiation in MSS Pancreatic Cancer
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI